Introduction
KalVista (KALV) revealed their fiscal year financial results this morning. Here are some key points:
- Phase 2 KVD900 HAE data due before end of year.
- After BioCryst (BCRX) revealed underwhelming HAE data, KalVista will have a chance to differentiate themselves. This could be an interesting, value-creating asset, but it is not KalVista's lead candidate.
- Phase 2 KVD001 DME data due before end of year.
- This is KalVista's lead program in which 001 revealed promising phase 1 data for this important indication that lacks substantive second-line treatment. It is no wonder